Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...
Banner Image
Mobile banner image

Pfizer Oncology
Development

Overview - by Phase

Geo Regions

View studies/programs by

Cancer Type Phase
Cancer types
Phases
Study status

Phase 1

Presentation Vepdegestrant (ARV-471)* + Atirmociclib | PF-07220060

Vepdegestrant (ARV-471)* + Atirmociclib | PF-07220060

PROTAC Estrogen Receptor Degrader
CDK4 Inhibitor
Phase 1
Presentation Tegtociclib | PF-07104091 + Atirmociclib | PF-07220060

Tegtociclib | PF-07104091 + Atirmociclib | PF-07220060

CDK2 Inhibitor
CDK4 Inhibitor
Phase 1
Presentation CEACAM5-directed Antibody Drug Conjugate

CEACAM5-directed Antibody Drug Conjugate

PF-08046050
Phase 1
Presentation Claturafenib | PF-07799933

Claturafenib | PF-07799933

BRAFi
Phase 1
rotating image for Disitamab vedotin

Disitamab vedotin | PF-08046051

HER2-directed Antibody Drug Conjugate
Phase 1
image representing elranatamab

Elranatamab

BCMA-CD3 Bispecific Antibody
Phase 1
rotating image for Enfortumab vedotin

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate
Phase 1
rotating gif of PF-08046054, SGN-PDL1V

Fetrastobart vedotin (Fetra-V) | PF-08046054

PDL1V | PD-L1-directed Antibody Drug Conjugate
Phase 1
Presentation Histone Lysine Acetyltransferase Inhibitor

Histone Lysine Acetyltransferase Inhibitor

PF-08032562 | KAT6/7
Phase 1
Presentation Integrin Beta-6 (IB6) Directed ADC

Integrin Beta-6 (IB6) Directed ADC

PF-08052667 | B6N
Phase 1
Presentation Integrin Beta-6 (IB6) Directed Top1 Inhibitor

Integrin Beta-6 (IB6) Directed Top1 Inhibitor

PF-08046876 | B6C
Phase 1
Presentation KRAS Inhibitor

KRAS Inhibitor

PF-07934040
Phase 1
Presentation Mevrometostat | PF-06821497

Mevrometostat | PF-06821497

EZH2 Inhibitor
Phase 1
rotating gif for Non-Fucosylated CD70-directed Antibody

Non-Fucosylated CD70-directed Antibody

PF-08046040 
Phase 1
Presentation Vepdegestrant (ARV-471)* + Palbociclib

Vepdegestrant (ARV-471)* + Palbociclib

PROTAC Estrogen Receptor Degrader
CDK4/6 Inhibitor
Phase 1
Presentation PD-1 x VEGF Bispecific Antibody

PD-1 x VEGF Bispecific Antibody

PF-08634404 (SSGJ-707)
Phase 1
Presentation Polfurmetinib | PF-07799544

Polfurmetinib | PF-07799544

MEK Brain Penetrant Inhibitor
Phase 1
Presentation Prifetrastat | PF-07248144

Prifetrastat | PF-07248144

KAT6 A/B Inhibitor
Phase 1
green molecule rotates

Sigvotatug vedotin

Integrin beta-6 directed Antibody Drug Conjugate
Phase 1
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor
Phase 1
Presentation Vepdegestrant (ARV-471)*

Vepdegestrant (ARV-471)*

PROTAC Estrogen Receptor Degrader
Phase 1

Phase 2

Presentation Vepdegestrant (ARV-471)* + Atirmociclib | PF-07220060

Vepdegestrant (ARV-471)* + Atirmociclib | PF-07220060

PROTAC Estrogen Receptor Degrader
CDK4 Inhibitor
Phase 2
Presentation Atirmociclib | PF-07220060

Atirmociclib | PF-07220060

CDK4 Inhibitor
Phase 2
Presentation Tegtociclib | PF-07104091 + Atirmociclib | PF-07220060

Tegtociclib | PF-07104091 + Atirmociclib | PF-07220060

CDK2 Inhibitor
CDK4 Inhibitor
Phase 2
rotating image for Brentuximab vedotin

Brentuximab vedotin

CD30-directed Antibody Drug Conjugate
Phase 2
rotating image for Disitamab vedotin

Disitamab vedotin | PF-08046051

HER2-directed Antibody Drug Conjugate
Phase 2
image representing elranatamab

Elranatamab

BCMA-CD3 Bispecific Antibody
Phase 2
Presentation Encorafenib

Encorafenib

BRAF Inhibitor
Phase 2
rotating image for Enfortumab vedotin

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate
Phase 2
Image representing palbociclib

Palbociclib

CDK4/6 Inhibitor
Phase 2
Presentation Vepdegestrant (ARV-471)* + Palbociclib

Vepdegestrant (ARV-471)* + Palbociclib

PROTAC Estrogen Receptor Degrader
CDK4/6 Inhibitor
Phase 2
Presentation PD-1 x VEGF Bispecific Antibody

PD-1 x VEGF Bispecific Antibody

PF-08634404 (SSGJ-707)
Phase 2
Presentation Ponsegromab | PF-06946860

Ponsegromab | PF-06946860

GDF-15 Monoclonal Antibody

GDF-15 Monocolonal Antibody
Phase 2
Presentation Prifetrastat | PF-07248144

Prifetrastat | PF-07248144

KAT6 A/B Inhibitor
Phase 2
Presentation Sasanlimab

Sasanlimab

Anti-PD-1 Monoclonal Antibody (mAb)
Phase 2
Presentation Tegtociclib | PF-07104091

Tegtociclib | PF-07104091

CDK2 Inhibitor
Phase 2
rotating image of Tisotumab vedotin

Tisotumab vedotin

TF-directed Antibody Drug Conjugate
Phase 2
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor
Phase 2
Presentation Vepdegestrant (ARV-471)*

Vepdegestrant (ARV-471)*

PROTAC Estrogen Receptor Degrader
Phase 2

Phase 3

Presentation Atirmociclib | PF-07220060

Atirmociclib | PF-07220060

CDK4 Inhibitor
Phase 3
Presentation Encorafenib + Binimetinib

Encorafenib + Binimetinib

BRAF Inhibitor
MEK Inhibitor
Phase 3
rotating image for Brentuximab vedotin

Brentuximab vedotin

CD30-directed Antibody Drug Conjugate
Phase 3
rotating image for Disitamab vedotin

Disitamab vedotin | PF-08046051

HER2-directed Antibody Drug Conjugate
Phase 3
image representing elranatamab

Elranatamab

BCMA-CD3 Bispecific Antibody
Phase 3
Presentation Encorafenib

Encorafenib

BRAF Inhibitor
Phase 3
rotating image for Enfortumab vedotin

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate
Phase 3
rotating gif of PF-08046054, SGN-PDL1V

Fetrastobart vedotin (Fetra-V) | PF-08046054

PDL1V | PD-L1-directed Antibody Drug Conjugate
Phase 3
Presentation Mevrometostat | PF-06821497

Mevrometostat | PF-06821497

EZH2 Inhibitor
Phase 3
Presentation Vepdegestrant (ARV-471)* + Palbociclib

Vepdegestrant (ARV-471)* + Palbociclib

PROTAC Estrogen Receptor Degrader
CDK4/6 Inhibitor
Phase 3
Image representing palbociclib

Palbociclib

CDK4/6 Inhibitor
Phase 3
Presentation PD-1 x VEGF Bispecific Antibody

PD-1 x VEGF Bispecific Antibody

PF-08634404 (SSGJ-707)
Phase 3
Presentation Ponsegromab | PF-06946860

Ponsegromab | PF-06946860

GDF-15 Monoclonal Antibody

GDF-15 Monocolonal Antibody
Phase 3
Presentation Prifetrastat | PF-07248144

Prifetrastat | PF-07248144

KAT6 A/B Inhibitor
Phase 3
Presentation Sasanlimab

Sasanlimab

Anti-PD-1 Monoclonal Antibody (mAb)
Phase 3
green molecule rotates

Sigvotatug vedotin

Integrin beta-6 directed Antibody Drug Conjugate
Phase 3
Presentation Talazoparib

Talazoparib

PARP Inhibitor
Phase 3
rotating image of Tisotumab vedotin

Tisotumab vedotin

TF-directed Antibody Drug Conjugate
Phase 3
rotating image of Tucatinib

Tucatinib

HER2 Tyrosine Kinase inhibitor
Phase 3
Presentation Vepdegestrant (ARV-471)*

Vepdegestrant (ARV-471)*

PROTAC Estrogen Receptor Degrader
Phase 3

Efficacy and safety of these products, for the uses identified within, are currently under investigation. Regulatory approval of any of these products or uses is dependent on the completion of the study programs and review by regulatory authorities. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of May 5,2026

*Vepdegestrant is being co-developed with Arvinas.